Abbott wins FDA approval for updated heart failure monitoring device
March 2, 2026
The company redesigned the reader to fit in a carry-on suitcase and be easier to use day to day.
The company redesigned the reader to fit in a carry-on suitcase and be easier to use day to day.
Novocure (Nasdaq:NVCR) announced today that Japan’s Ministry of Health, Labour and Welfare (MHLW) approved reimbursement for its Optune Lua system.
Boston Scientific (NYSE: BSX)+ announced today that its Farapulse pulsed field ablation (PFA) system received expanded CE mark approval.
BD (NYSE: BDX)+ received FDA 510(k) clearance for its Surgiphor 1000mL antimicrobial irrigation system, the company announced today.
Senseonics (NYSE:SENS) posted fourth-quarter results that proved mixed compared to Wall Street forecasts alongside a major pipeline announcement.
STOCKHOLM, March 2, 2026 /PRNewswire/ — SciBase Holding AB (“SciBase”) (STO: SCIB), a leading developer of AI-based diagnostic solutions for skin disorders, today announced that it has received approval by FDA for its supplement to extend the labelling to include other healthcare professionals and not only dermatologists to perform the Nevisense procedure
DENVER, March 2, 2026 /PRNewswire/ — Ultrasound AI, a pioneer in artificial intelligence applications for medical imaging, today announced it has received FDA De Novo clearance for its flagship Delivery Date AI technology, a cloud-based SaMD that determines a Predicted Delivery Date (PDD) solely from standard ultrasound images and seamless integration into current OB/MFM prenatal visit workflows; PDD is provided in real-time for actionable decision-making by the clinical team.
Lasers cut precisely and without contact—ideal for surgery. The problem is that in hard tissues such as bone, they are too slow and do not cut deep enough. Researchers at the University of Basel have now demonstrated a way to cut much deeper and faster with a surgical laser than with previous laser systems.
Synergy Spine Solutions®, a medical device company focused on improving the quality of life for patients undergoing spine surgery, today announced it has received U.S. Food and Drug Administration (FDA) Premarket Approval (PMA) for the Synergy Disc® for 1-level indications at C3-C7.
Gene therapy has been successfully used to treat a number of diseases, including immune deficiencies, hereditary blindness, hemophilia and, recently, Huntington’s disease, a fatal neurological disorder.